GlassScriptPhysician profile
Kevin T DO
NPI 1811384001
$30,811.83
in general payments reported to CMS, 2019-2025
84 companies · $8,082 in 2025
The $8,082 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2021: $1,483 · 2022: $4,937 · 2023: $7,686 · 2024: $8,440 · 2025: $8,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22K · Long Term Medical Supply Or Device Loan: $1,981 · Education: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21,883.63 |
| Long Term Medical Supply Or Device Loan | $1,980.59 |
| Education | $343.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,527.22 | 2021-2025 | |
| Merz North America, INC. | $2,915.76 | 2019-2025 | Xeomin |
| Astrazeneca Pharmaceuticals LP | $1,811.23 | 2021-2025 | Calquence, Imfinzi, Enhertu |
| Incyte Corporation | $1,656.00 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Biotech, INC. | $1,442.87 | 2021-2025 | Darzalex, Tecvayli, Rybrevant |
| Merck Sharp & Dohme LLC | $1,075.74 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Eisai INC. | $892.93 | 2021-2025 | |
| Gilead Sciences, INC. | $843.87 | 2021-2025 | Trodelvy, Biktarvy |
| Celgene Corporation | $760.41 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Exelixis INC. | $746.92 | 2021-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $735.39 | 2021-2025 | Opdivo, Opdualag |
| Pfizer INC. | $731.44 | 2021-2025 | |
| Seagen INC. | $730.03 | 2019-2023 | Padcev, Tukysa, Tivdak |
| Lilly USA, LLC | $725.54 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Daiichi Sankyo INC. | $646.87 | 2021-2025 | Enhertu, Datroway |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $641.82 | 2021-2025 | Fruzaqla, Alunbrig, Iclusig |
| Alexion Pharmaceuticals, INC. | $598.81 | 2021-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $587.73 | 2021-2025 | |
| Glaxosmithkline, LLC. | $574.51 | 2021-2025 | Ojjaara, Jemperli, Blenrep |
| Karyopharm Therapeutics INC. | $552.39 | 2022-2025 | Xpovio |
| Abbvie INC. | $546.38 | 2022-2025 | Venclexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.21 | 2021-2025 | Gilotrif |
| Puma Biotechnology, INC. | $452.24 | 2023-2025 | Nerlynx |
| Stemline Therapeutics INC. | $428.88 | 2023-2025 | Orserdu, Elzonris |
| Astellas Pharma US INC | $387.58 | 2022-2024 | Xtandi, Padcev, Xospata |
| Regeneron Healthcare Solutions, INC. | $384.88 | 2024-2025 | Libtayo |
| Amgen INC. | $357.23 | 2021-2023 | Kyprolis, Vectibix, Xgeva |
| Pharmacyclics LLC, An Abbvie Company | $310.87 | 2021-2023 | Imbruvica, Epkinly |
| Genentech USA, INC. | $288.42 | 2022-2024 | Tecentriq, Phesgo, Itovebi |
| Beigene USA, INC. | $281.03 | 2021-2025 | Brukinsa, Tevimbra |
| Rigel Pharmaceuticals, INC. | $259.33 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Genzyme Corporation | $239.60 | 2021-2025 | |
| Array Biopharma INC | $237.22 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Emd Serono, INC. | $223.05 | 2021-2025 | Bavencio |
| Blueprint Medicines Corporation | $217.71 | 2022-2025 | Ayvakit |
| Sobi, INC | $208.81 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $198.68 | 2023-2025 | Fotivda |
| Adc Therapeutics America, INC. | $195.61 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $183.21 | 2023-2025 | Orgovyx |
| Coherus Oncology, INC. | $182.43 | 2021-2025 | Loqtorzi |
| Taiho Oncology, INC. | $172.83 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $164.67 | 2023-2025 | Enjaymo, Sylvant |
| Beone Medicines USA, INC. | $157.96 | 2025 | Brukinsa, Tevimbra |
| Ipsen Biopharmaceuticals, INC | $157.54 | 2022-2025 | Onivyde, Somatuline Depot |
| Pharmaessentia USA Corporation | $143.99 | 2024-2025 | Besremi |
| Genmab U.S., INC. | $133.32 | 2023-2025 | Epkinly |
| Fresenius Kabi USA, LLC | $124.78 | 2024 | Smoflipid |
| Janssen Pharmaceuticals, INC | $117.18 | 2022 | |
| Tersera Therapeutics LLC | $107.55 | 2022-2025 | Zoladex |
| Kite Pharma, INC. | $87.73 | 2021-2023 | |
| Geron Corporation | $80.10 | 2024-2025 | Rytelo |
| Servier Pharmaceuticals LLC | $78.44 | 2022-2024 | |
| Morphosys, US INC. | $74.73 | 2022-2023 | Monjuvi |
| Caris Mpi, INC. | $59.94 | 2025 | Mi Cancer Seek |
| Myovant Sciences INC. | $56.40 | 2022 | |
| Deciphera Pharmaceuticals INC. | $55.54 | 2023 | Qinlock |
| Legend Biotech USA INC. | $55.29 | 2025 | Carvykti |
| Jazz Pharmaceuticals INC. | $52.63 | 2025 | |
| Adaptive Biotechnologies Corporation | $51.81 | 2022-2023 | Clonoseq |
| Pharmacosmos Therapeutics INC. | $44.09 | 2025 | Monoferric |
| Boston Scientific Corporation | $44.04 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Verity Pharmaceuticals INC. | $41.34 | 2023 | Trelstar |
| Agios Pharmaceuticals, INC. | $39.18 | 2023 | Pyrukynd |
| Mirati Therapeutics, INC. | $37.44 | 2023-2024 | Krazati |
| Spectrum Pharmaceuticals INC. | $37.25 | 2023-2025 | Rolvedon |
| Syndax Pharmaceuticals, INC. | $33.49 | 2025 | |
| Revance Therapeutics, INC. | $31.18 | 2025 | Daxxify |
| Alnylam Pharmaceuticals INC. | $30.06 | 2025 | Givlaari |
| Tempus Ai, INC | $29.48 | 2024 | |
| Emmaus Medical, INC. | $24.19 | 2022-2024 | Endari |
| Acorda Therapeutics, INC | $21.71 | 2019 | |
| Immunogen, INC. | $21.30 | 2023 | Elahere |
| Fennec Pharmaceuticals, INC. | $21.14 | 2025 | Fyarro |
| Azurity Pharmaceuticals, INC. | $19.38 | 2025 | Danziten |
| Tg Therapeutics, INC. | $18.81 | 2021 | |
| Epizyme, INC. | $17.57 | 2022 | |
| Iovance Biotherapeutics, INC. | $17.57 | 2025 | Amtagvi |
| Kyowa Kirin, INC. | $16.57 | 2025 | |
| Chiesi USA, INC. | $15.16 | 2025 | Ferriprox |
| Apellis Pharmaceuticals, INC. | $14.70 | 2025 | Empaveli |
| Ge Healthcare | $13.24 | 2021 | |
| Foundation Medicine, INC. | $12.36 | 2022 | |
| Dova Pharmaceuticals | $12.19 | 2021 | |
| Eusa Pharma (US) LLC | $12.11 | 2022 |
Drugs and devices associated with these payments
Kisqali $2,240Xeomin $1,133Keytruda $933Enhertu $776Lenvima $744Jakafi $686Imbruvica $597Ultomiris $568Calquence $516Cabometyx $514Jaypirca $493Epkinly $462Verzenio $452Xpovio $430Orserdu $407Orgovyx $397Libtayo $385Monjuvi $380Reblozyl $355Nubeqa $351Fruzaqla $337Opdivo $332Darzalex $326Retevmo $325Tecvayli $320Xtandi $312Imfinzi $310Lynparza $308Pluvicto $307Rybrevant $296Nerlynx $287Brukinsa $281Welireg $275Pemazyre $270Ojjaara $267Xofigo $266Scemblix $230Carvykti $220Opdualag $203Tavalisse $201Rezlidhia $201Fotivda $199Braftovi $198Mektovi $198Padcev $189Gilotrif $180Zynlonta $179Ibrance $164Lutathera $159Tecentriq $158Comirnaty $153Trodelvy $149Tukysa $147Ayvakit $145Somatuline Depot $144Onivyde $144Besremi $144Talzenna $143Talvey $139Smoflipid $125Sarclisa $124Inqovi $122Lonsurf $122Venclexta $119Adcetris $118Erleada $116Fabhalta $114Biktarvy $113Piqray $111Jemperli $108Paxlovid $106Doptelet $106Alunbrig $103Elahere $100Udenyca $99.61Keytruda Qlex $97.63Enjaymo $94.83Tevimbra $93.37Elrexfio $89.76Xalkori $89.05Stivarga $84.94Vitrakvi $84.94Pomalyst $82.53Rytelo $80.10Bosulif $71.92Blenrep $70.38Sylvant $69.84Lorbrena $66.40Promacta $64.27Mekinist $63.60Phesgo $61.93Iclusig $60.84Mi Cancer Seek $59.94Zoladex $58.77Akeega $56.01Qinlock $55.54Zejula $52.37Xospata $49.12Ninlaro $44.62Vonjo $44.56
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.